Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(5 years from now) | |
US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(12 years from now) | |
US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(12 years from now) | |
US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(12 years from now) | |
US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
US11246850 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Feb 5, 2023 |
Market Authorisation Date: 27 March, 2013
Treatment: Method of treating multiple sclerosis; Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic